Sign up
Log in
Why GQG, Imugene, Mirvac, and Temple & Webster shares are pushing higher
Share
Listen to the news
Two smiling work colleagues discuss an investment or business plan at their office.

In afternoon trade on Friday, the S&P/ASX 200 Index (ASX: XJO) is on course to record a decent gain. At the time of writing, the benchmark index is up 0.4% to 8,574.7 points.

Four ASX shares that are rising more than most today are listed below. Here's why they are charging higher:

GQG Partners Inc (ASX: GQG)

The GQG Partners share price is up 5.5% to $2.50. This morning, this investment company released its full year results and revealed a strong set of numbers. GQG Partners posted a 46.9% increase in net revenue to US$760.4 million and a 50.4% jump in distributable earnings to US$447.9 million. GQG Partners' CEO and executive director, Tim Carver, said: "The growth in FUM reflects strong performance from our investment team and another great effort from our business team. The increase in FUM led to net revenue growth of 46.9% to US$760.4 million during 2024. Net operating income increased 50.4% to US$577.9 million during the same period, reflecting an increase in average funds under management partially offset by an increase in expenses as GQG continues to invest in talent and overall business activities."

Imugene Ltd (ASX: IMU)

The Imugene share price is up 10% to 4.3 cents. This follows the release of a trial update from the clinical-stage immuno-oncology company. Imugene revealed more positive results from its Phase 1b clinical trial evaluating azer-cel in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Chief Medical Officer Dr Paul Woodard said: "All four Complete Responses in Cohort B were achieved in patients who had failed at least 4 lines of therapy in this hard-to-treat population, including autologous CAR T therapy. This suggests that azer-cel, in combination with IL-2, may offer a meaningful therapeutic option where other treatments have not succeeded."

Mirvac Group (ASX: MGR)

The Mirvac share price is up 4% to $2.08. Investors have been buying the property company's shares following the release of its half year results. Mirvac reported an operating profit of $236 million, which represents 6 cent per share. As a result, the company is on track to deliver on its full year guidance of between 12 cents to 12.3 cents per share in FY 2025.

Temple & Webster Group Ltd (ASX: TPW)

The Temple & Webster share price is up a further 8% to $17.45. Investors have been bidding the furniture and homeware retailer's shares higher this week following the release of its half year results. Temple & Webster reported a 23.6% increase in revenue to $313.7 million and a 118% jump in net profit after tax to $9 million. The company's CEO, Mark Coulter, said: "Temple & Webster has again delivered a record half, with strong performance against all key metrics, against a challenging macro and consumer backdrop."

The post Why GQG, Imugene, Mirvac, and Temple & Webster shares are pushing higher appeared first on The Motley Fool Australia.

Motley Fool contributor James Mickleboro has positions in Temple & Webster Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Temple & Webster Group. The Motley Fool Australia has recommended Temple & Webster Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2025

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.